



September 1, 2025

To whom it may concern:

|                                |  |
|--------------------------------|--|
| Company                        | CareNet, Inc.  |
| Representative                 | Katsuhiro Fujii, President and Representative Director |
| (Code number: 2150, TSE Prime) |  |
| Contact:                       | Hiromi Sato, General Manager, Corporate Division       |
| (Phone: +81-3-5214-5800)       |  |

|                |   |
|----------------|---|
| Company        | Curie 1, K.K.                                 |
| Representative | Ezekiel Daniel Arlin, Representative Director |

**(Amendment) Notice Regarding Amendment to “Notice Regarding Commencement of the Tender Offer for Shares of CareNet, Inc. (Code number: 2150) by Curie 1, K.K.” in Connection with Filing of Amendment to Tender Offer Registration Statement by Curie 1, K.K.**

On September 1, 2025, Curie 1, K.K. filed an Amendment to Tender Offer Registration Statement (including matters amended by the Amendment to Tender Offer Registration Statement submitted on August 25, 2025) with the Director of the Kanto Local Finance Bureau pursuant to the provision of Article 27-8, Paragraph 2 of the Financial Instruments and Exchange Act. In connection therewith, it has amended some of the matters stated in “Notice Regarding Commencement of the Tender Offer for Shares of CareNet, Inc. (Code number: 2150) by Curie 1, K.K.” dated August 13, 2025, as attached.

-End-

This document is being disclosed by Curie 1, K.K. (the “Tender Offeror”) pursuant to Article 30, paragraph (1), item (iv) of the Order for Enforcement of the Financial Instruments and Exchange Act based on a request made to CareNet, Inc. (the “Target Company”).

(Attachment)

(Amendment) Notice Regarding Amendment to “Notice Regarding Commencement of the Tender Offer for Shares of CareNet, Inc. (Code number: 2150) by Curie 1, K.K.” in Connection with Filing of Amendment to Tender Offer Registration Statement by Curie 1, K.K. dated September 1, 2025

September 1, 2025

To whom it may concern:

|                |  |
|----------------|--|
| Company        | Curie 1, K.K.                                    |
| Representative | Ezekiel Daniel Arlin,<br>Representative Director |

**(Amendment) Notice Regarding Amendment to “Notice Regarding Commencement of the Tender Offer for Shares of CareNet, Inc. (Code number: 2150) by Curie 1, K.K.” in Connection with Filing of Amendment to Tender Offer Registration Statement by Curie 1, K.K.**

Curie 1, K.K. (the “Tender Offeror”) hereby announces that on August 13, 2025, it decided to acquire the common shares of CareNet, Inc. (Code number: 2150, listed on the Prime Market of Tokyo Stock Exchange, Inc. (the “Tokyo Stock Exchange”); the “Target Company,” and the shares to be acquired, the “Target Company Shares”) through a tender offer (the “Tender Offer”) under the Financial Instruments and Exchange Act (Act No. 25 of 1948, as amended) and commenced the Tender Offer on August 14, 2025.

On September 1, 2025, the Tender Offeror additionally entered into tender agreements with K.S.K. Co., Ltd. (number of shares held: 1,095,600 shares, ownership ratio: 2.61%) and VITAL-NET, Inc. (number of shares held: 1,043,600 shares, ownership ratio: 2.49%) under which each agreed to tender all shares in the Target Company they hold in the Tender Offer. The Tender Offeror submitted the Amendment to Tender Offer Registration Statement (including matters amended by the Amendment to Tender Offer Registration Statement submitted on August 25, 2025), pursuant to Article 27-8, paragraph (2) of the Act, in order to amend certain matters contained in the Tender Offer Registration Statement submitted on August 14, 2025.

The Tender Offeror hereby announces that, in connection therewith, it has amended some of the matters stated in “Notice Regarding Commencement of the Tender Offer for Shares of CareNet, Inc. (Code number: 2150) by Curie 1, K.K.” dated August 13, 2025 (the “Press Release Regarding Commencement of the Tender Offer”) as detailed below. Please note that these amendments do not include any changes to the terms of purchase, etc. as defined in Article 27-3, Paragraph 2, Item (1) of the Act.

End

## I. Details of Amendment to the Press Release Regarding Commencement of the Tender Offer

The Tender Offeror hereby makes the following amendment to the Press Release Regarding Commencement of the Tender Offer. The underlined text indicates matters that have been amended.

(Before Amendment)

(Omitted)

In connection with the Tender Offer, the Tender Offeror entered into a tender offer agreement (the “Tender Offer Agreement”) dated August 13, 2025 with the Target Company in relation to the Transactions and entered into (i) a tender agreement with MIJ Healthcare No. 1 Investment Limited Partnership, the largest shareholder of the Target Company (“MIJ Healthcare”) (number of shares owned: 6,736,000 shares; ownership ratio: 16.07%), (ii) a tender agreement with Millennium Partners Co., Ltd., a shareholder of the Target Company (“Millennium Partners”) (number of shares held: 220,000 shares, ownership percentage: 0.52%) and (iii) a tender agreement (the Tender Agreements entered into with the Tendering Shareholders are collectively referred to as the “Tender Agreements”) with Mr. Mitsuhiro Hata (collectively with MIJ Healthcare and Millennium Partners, the “Tendering Shareholders”), a shareholder of the Target Company, the representative director and chairman of Medical Incubator Japan K.K. which is an general partner of MIJ Healthcare, and the representative director of Millennium Partners (Number of shares held: 180,000 shares, Ownership percentage: 0.43%) respectively and the Tendering Shareholders agree to tender all of the Target Company Shares held by each Tendering Shareholder (total number of shares owned: 7,136,000 shares, total ownership percentage: 17.03%) upon the commencement of the Tender Offer. For an overview of the Tender Offer Agreement and the Tender Agreements, please refer to “(6) Matters Concerning Material Agreements Related to the Tender Offer” under “(A)Tender Offer Agreement” and “(B) Tender Agreements” of the tender offer registration statement for the Tender Offer (the “Tender Offer Registration Statement”).

(Omitted)

(After Amendment)

(Omitted)

In connection with the Tender Offer, the Tender Offeror entered into a tender offer agreement (the “Tender Offer Agreement”) dated August 13, 2025 with the Target Company in relation to the Transactions and entered into (i) a tender agreement with MIJ Healthcare No. 1 Investment Limited Partnership, the largest shareholder of the Target Company (“MIJ Healthcare”) (number of shares owned: 6,736,000 shares; ownership ratio: 16.07%), (ii) a tender agreement with

Millennium Partners Co., Ltd., a shareholder of the Target Company (“Millennium Partners”) (number of shares held: 220,000 shares, ownership percentage: 0.52%) and (iii) a tender agreement with Mr. Mitsuhiro Hata, a shareholder of the Target Company, the representative director and chairman of Medical Incubator Japan K.K. which is a general partner of MIJ Healthcare, and the representative director of Millennium Partners (Number of shares held: 180,000 shares, Ownership percentage: 0.43%) respectively. Subsequently, on September 1, 2025, the Tender Offeror additionally entered into (iv) a tender agreement (the “Tender Agreement (K.S.K.)”) with K.S.K. Co., Ltd. (“K.S.K.”), a shareholder of the Target Company (number of shares held: 1,095,600 shares; ownership percentage: 2.61%; the “Tendered Shares (K.S.K.)”), and (v) a tender agreement (the “Tender Agreement (Vitalnet”) with VITAL-NET, Inc. (“Vitalnet”; collectively with MIJ Healthcare, Millennium Partners, Mr. Mitsuhiro Hata, and K.S.K., the “Tendering Shareholders”), a shareholder of the Target Company (number of shares held: 1,043,600 shares; ownership percentage: 2.49%; the “Tendered Shares (Vitalnet”), respectively. For an overview of the Tender Offer Agreement and the Tender Agreements, please refer to “(6) Matters Concerning Material Agreements Related to the Tender Offer” under “(A)Tender Offer Agreement” and “(B) Tender Agreements” of the tender offer registration statement for the Tender Offer (the “Tender Offer Registration Statement”).

(Omitted)

-End-

**Restrictions on Solicitation** This Press Release is a public announcement to disclose the Tender Offer and has not been prepared for the purpose of soliciting the sale of shares. If you wish to tender your shares, please be sure to carefully read the Tender Offer Explanation Statement concerning the Tender Offer and make your decision at your own discretion. This Press Release does not constitute, or form a part of, an offer to sell or a solicitation of an offer to sell or a solicitation of an offer to purchase securities, and neither this Press Release (in whole or in part) nor its distribution will form the basis of, or be relied on in connection with, an agreement related to the Tender Offer.

**U.S. Regulations** The Tender Offer will be conducted in accordance with the procedures and information disclosure standards prescribed by Japanese law, which might differ from the procedures and information disclosure standards in the United States. Specifically, Section 13(e) or Section 14(d) of the U.S. Securities Exchange Act of 1934 (as amended, the “Securities Exchange Act of 1934”) and the rules promulgated in those Sections do not apply to the Tender Offer, and the Tender Offer does not conform to the procedures and standards prescribed therein. All financial information contained in or referred to in this press release and the documents referenced in this press release is based on Japanese accounting standards, is not based on U.S. accounting standards, and might not be equivalent to or comparable with financial information prepared in accordance with U.S. accounting standards. In addition, since the Tender Offeror is a corporation established outside the United States and its officers are not residents of the United States, it might be difficult to exercise rights or make claims under U.S. securities laws. In addition, it might not be possible to initiate legal proceedings in courts outside the United States against a non-U.S. corporation and its officers based on violations of U.S. securities laws. Furthermore, the jurisdiction of U.S. courts might not necessarily extend to a non-U.S. corporation or its subsidiaries and affiliates. All procedures relating to the Tender Offer are to be conducted in Japanese. Although all or some of the documents relating to the Tender Offer might be prepared in English, if there is any discrepancy between the English and Japanese versions, the Japanese version will prevail. The financial advisors of the Tender Offeror and the Target Company, and the tender offer agent (including their respective affiliates) may, in the ordinary course of their business and to the extent permitted under Japanese financial instruments exchange laws and other applicable laws and regulations, and in accordance with the requirements of Rule 14e-5(b) under the U.S. Securities Exchange Act of 1934, purchase or take actions to purchase shares of the Target Company for their own account or for the account of their clients, outside the Tender Offer, either before the commencement of the Tender Offer or during the tender offer period. If information regarding any such purchase is disclosed in Japan, it will be disclosed in English on the website of the party making that purchase (or by another disclosure method).

**Forward-Looking Statements** This Press Release contains “forward-looking statements” as defined in Section 27A of the U.S. Securities Act of 1933 (as amended) and Section 21E of the U.S. Securities Exchange Act of 1934. Actual results might differ materially from the projections or other forward-looking statements, whether expressed or implied, due to known or unknown risks, uncertainties, or other factors. None of the Tender Offeror or any of its affiliates make any commitment that the projections or other forward-looking statements, whether expressed or implied, will ultimately be accurate. The forward-looking statements in this Press Release are based on information available to the Tender Offeror as of the date of this Press Release. Except

as required by laws or the rules of a financial instruments exchange, neither the Tender Offeror nor its affiliates assume any obligation to update or revise those statements to reflect future events or circumstances.

**Other Countries** The announcement, issuance, or distribution of this Press Release might be subject to legal restrictions in certain countries or regions. In such cases, please be aware of and comply with any such restrictions. The announcement, issuance, or distribution of this Press Release does not constitute a solicitation of an offer to purchase or sell share certificates in connection with the Tender Offer and is to be deemed solely as the distribution of materials for informational purposes.